Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must be aged 18 to less than 75 years.~2. Each patient must be reliable, have a level of understanding sufficient to perform all tests and examinations required by the protocol, and must understand the nature of the study and have provided informed consent.~3. All female patients must test negative for pregnancy.~4. Females of breast-feeding potential must agree not to breastfeed an infant during the study and for 1 month following the last dose of study drug.~5. Male patients who are not surgically sterilized must agree to use a reliable method of birth control during the study and for 1 month following the last dose of study drug.~6. Patients must fulfill the diagnostic criteria for bipolar I disorder, most recent episode depressed, as defined in the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR).~7. Patients must have experienced, in the opinion of the investigator, at least one previous manic or mixed episode, as defined in the DSM-IV-TR.~8. Patients must have a current Young Mania Rating Scale (YMRS) Total score =\<8.~Exclusion Criteria:~1. Is investigator site personnel directly affiliated with this study or their immediate families.~2. Is a Lilly employee.~3. Has previously completed or withdrawn from this study or any other study investigating olanzapine.~4. Is pregnant or nursing.~5. Has a serious, unstable illness such that death is anticipated within 1 year or intensive care unit hospitalization for the disease is anticipated within 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Pre-Olanzapine (Type: EXPERIMENTAL): Participants who received olanzapine 5-20 mg/day in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.
- Pre-Placebo (Type: EXPERIMENTAL): Participants who received placebo in acute phase of Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.
- New Olanzapine (Type: EXPERIMENTAL): Participants who did not participate in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).